SCHEMBL25980773

SCHEMBL25980773

CCc1cc(N(Cc2ccc(C(=O)NOI)cc2)C(=O)N2CCC(C)CC2)ccc1C

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MERTK Q12866 3/20 0.40
AXL P30530 2/20 0.40
HPGD P15428 3/20 0.39
ALDH1A1 P00352 3/20 0.39
TP53 P04637 1/20 0.39
F2 P00734 3/20 0.38
PRSS1 P07477 1/20 0.38
KCNH2 Q12809 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TNKS O95271 2/20 0.35
TNKS2 Q9H2K2 2/20 0.35
KMT2A Q03164 1/20 0.35
MAPK14 Q16539 1/20 0.35
POLB P06746 1/20 0.35
LMNA P02545 1/20 0.35
GLA P06280 1/20 0.34
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25980762 0.90 HDAC1 (0.39) HPGDALDH1A1F2PRSS1KCNH2
SCHEMBL25980814 0.89 ALDH1A1 (0.40) ALDH1A1KCNH2SMN1; SMN2KMT2AMAPK14
SCHEMBL25980818 0.89 SMN1; SMN2 (0.38) HPGDALDH1A1TP53KCNH2SMN1; SMN2
SCHEMBL25980785 0.88 HDAC1 (0.40) HPGDALDH1A1SMN1; SMN2KMT2A
SCHEMBL25980807 0.88 L3MBTL1 (0.38) HPGDALDH1A1KCNH2SMN1; SMN2KMT2A
SCHEMBL25981775 0.78 HPGD (0.47) HPGDALDH1A1TP53SMN1; SMN2KMT2A
SCHEMBL25979300 0.77 HTT (0.49) HPGDALDH1A1F2PRSS1SMN1; SMN2
SCHEMBL25979600 0.77 HDAC6 (0.41) HPGDALDH1A1TP53KMT2A
SCHEMBL17618035 0.72 RAB9A (0.47) HPGDALDH1A1F2PRSS1KMT2A
SCHEMBL16211486 0.72 KMT2A (0.43) HPGDSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230248735-A1 COMPOSITIONS FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230248735-A1 COMPOSITIONS FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) NR1H2, CFTR, CYP11B2 MERTK 4252/4885AXL 4809/4885HPGD 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.